The GlycoMimetics management team consists of industry leaders with deep experience in the pharmaceutical/biotechnology industry garnered at world-class organizations such as Novartis, New Enterprise Associates, the National Institutes of Health, Biosynexus, MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), and others. Our leadership team works closely with our Board of Directors to continue to drive the success of our programs.
- Rachel K. King, Chief Executive Officer
- John Magnani, Ph.D., Vice President and Chief Scientific Officer
- Helen Thackray, M.D., FAAP, Vice President of Clinical Development and Chief Medical Officer
- Brian Hahn, Chief Financial Officer
Rachel K. King, Chief Executive Officer
Before co-founding GlycoMimetics, Mrs. King was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Mrs. King came to NEA after serving as a Senior Vice President of Novartis Corporation. Before joining Novartis, Mrs. King spent ten years with Genetic Therapy, Inc. (GTI), a biotechnology company, where she served in a number of roles as part of the executive team, through that company’s initial public offering and later acquisition by Novartis. After the acquisition by Novartis, she served as CEO of Genetic Therapy, which was then a wholly owned subsidiary of Novartis. Mrs. King also worked previously at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston. She received her B.A. degree from Dartmouth College and her M.B.A. from Harvard Business School. Mrs. King currently serves as Chair of the Board of the Biotechnology Industry Organization (BIO). At BIO, she is also on the Executive Committee and is a former Chair of the Emerging Companies Governing Body. She is also Chair of the Maryland Life Sciences Advisory Board appointed by Governor Martin O’Malley.
John Magnani, Ph.D., Vice President and Chief Scientific Officer
John Magnani is an expert in glycobiology having identified and characterized many carbohydrate tumor antigens, such as CA19-9, and developed fundamental technology for the identification of functional carbohydrate epitopes. Dr. Magnani is the discoverer of Sialyl Lewisa and its functions. He was the first to identify the binding domain to the selectins common to both Sialyl Lewisa and Sialyl Lewisx and used this information to develop potent selectin antagonists. Prior to co-founding GlycoMimetics, Dr. Magnani founded and led GlycoTech Corporation as its President and CEO. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its Vice President of Research. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, (NIADDK) of the National Institutes of Health. He remained at the NIH for ten years, finally serving as a tenured Research Chemist.
Helen Thackray, M.D., FAAP, Vice President of Clinical Development and Chief Medical Officer
Dr. Thackray joined GlycoMimetics in 2006. She has extensive experience in design and execution of clinical trials, including early-stage development of novel biologics and small molecules through to successful clinical proof of concept. In addition, she has a particular interest in Orphan Drug and Fast Track products. At GlycoMimetics, she oversees development of investigational products for the company, including a recently completed Phase 2 clinical program in sickle cell disease, a program for cancer and thrombosis, and supportive manufacturing and preclinical work. Concurrent to her position at GlycoMimetics, Dr. Thackray holds an appointment as Assistant Clinical Professor of Pediatrics at the George Washington University School of Medicine and is a practicing board-certified hospital-based pediatrician. Previously, she was Vice President of Clinical Product Development at Biosynexus, Inc. While at Biosynexus, Dr. Thackray oversaw the complex clinical development of a biologic product in hospitalized neonates. Prior to entering industry, she completed a pediatrics residency at Children’s National Medical Center in Washington, D.C., followed by a year as Pediatric Chief Resident and Adjunct Instructor in Pediatrics. She served as a Medical Genetics Fellow at the National Human Genome Research Institute of the National Institutes of Health. Dr. Thackray received her B.S. from Stanford University and her M.D. from George Washington University School of Medicine. She is a member of the Institutional Review Board of Holy Cross Hospital; recently served on the BIO PDUFA V Technical Discussions team; and is a Fellow of the American Academy of Pediatrics.
Brian Hahn, Chief Financial Officer
Mr. Hahn has over 15 years of senior financial and operations experience in emerging organizations. He joined GlycoMimetics in 2010. Previously, Mr. Hahn served as Executive Director of Finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), a publicly traded specialty pharmaceutical company. Prior to Advancis, he was a senior accountant with Bering Truck Corporation. He began his career as an auditor for the Bank of Clarke County. Over the last ten years, Mr. Hahn has worked with life science companies from early stages (including an initial public offering) through product launch. He has broad experience in developing strategic plans, creating business models, establishing accounting and auditing systems, and ensuring Sarbanes-Oxley compliance. Currently, Mr. Hahn serves as Chair for the Financial Executive Committee (FEF) of the Tech Council of MD and as a member of the Steering Committee of the DC chapter of the Association for Bio Financial Officers (ABFO). He received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.